US-based pharmaceutical company Jaguar Health has issued secured notes in a private placement to raise $0.75m. The existing noteholder has subscribed to the placement.
The company has subsequently issued Series A convertible participating preferred shares in a private placement to Sagard Capital Partners (Sagard) to raise $9.19m.
The company has also issued 29.41 million shares in a private placement to raise $5m, which was subscribed to by other investors.
Jaguar Health plans to use the proceeds towards the commercialisation of FDA-approved product Mytesi and for the acquisition of Napo Pharmaceuticals.
China-based pharmaceutical company Sichuan Kelun Pharmaceutical Co (SKPC) has issued a 5.84% first tranche of bonds in a private placement to raise CNY400m ($63.3m).
The bonds are due for maturity in 2018 and will be subscribed to by institutional investors.
Guojin Securities has been appointed as the underwriter for the transaction.
US-based biopharmaceutical company PTC Therapeutics has issued four million shares of its common stock in a public offering.
The underwriters will be granted a 30-day option to buy an additional six million shares.
PTC Therapeutics plans to use the proceeds for funding clinical trials of its products, commercialisation of Translarna and Emflaza, and for general corporate requirements.
The company has appointed Credit Suisse Securities (USA), Citigroup Global Markets and RBC Capital Markets as book-running managers, and Wilmer Cutler Pickering Hale and Dorr as legal advisors for the transaction.
US-based biotechnology company Heron Therapeutics plans to issue shares of its common stock in an underwritten public offering.
The underwriters will have a 30-day option to buy an additional 15% of the shares.
The company plans to use the proceeds for the commercial promotion of HTX-011 upon FDA approval, and for marketing of SUSTOL and CINVANTI.
Gibson, Dunn & Crutcher has been appointed as the legal advisor for the transaction.
Eisai has signed an agreement with Nichi-Iko Pharmaceuticals to promote active pharmaceutical ingredient (API) business at its plant in Vizag, India.
Eisai will start co-promotion of Nichi-Iko’s products, while Nichi-Iko will commence co-promotion of Elmed Eisai’s products from October 2018, as part of the agreement.
Eisai will transfer 20% of the outstanding shares from its subsidiary Elmed Eisai to Nichi-Iko, as part of the transaction. Elmed Eisai will become a subsidiary of Nichi-Iko, upon completion of the transaction.
The transaction will help both Eisai and Nichi-Iko Pharma to expand and develop their generic pharmaceutical business.
Eisai is a pharmaceutical company based in Japan, while Nichi-Iko Pharmaceuticals, also based in Japan, is engaged in the production of generic drugs.